GPR132 and acute myeloid leukemia: Nonetheless, GPR132 agonist activation of a GPR132-Gs-PKA pathway interfered with mTOR signaling and promoted acute myeloid leukemia (AML) cell differentiation, suggesting a therapeutic approach to AML treatment [66].